INVO Fertility EBITDA per Share

What does INVO Fertility do? INVO Bioscience Inc generates revenue through its flagship product INVOcell, a medical device enabling intravaginal culture (IVC) for fertility treatment. The company commercializes its IVC technique by operating three INVO Centers in North America, offering patients an affordable alternative to in vitro fertilization (IVF). INVO Centers provide a more connected and intimate experience by incubating oocytes and sperm within the woman’s body, targeting individuals seeking accessible fertility care globally. The company also acquires existing IVF clinics to expand its market reach and integrate IVC into established fertility services. INVOcell and IVC are positioned as cost-effective solutions compared to traditional IVF, appealing to patients prioritizing affordability and a natural process. The commercial strategy focuses on opening new INVO Centers and acquiring IVF clinics, creating a dual revenue stream from device sales and procedure fees at affiliated centers. This approach targets the global assisted reproductive technology (ART) market, emphasizing inclusivity and accessibility for diverse patient segments. The company’s revenue model relies on direct patient treatment at INVO Centers and partnerships with acquired IVF clinics, where IVC procedures are integrated. By making fertility care more affordable and intimate, INVO Bioscience Inc addresses unmet needs in the ART sector, particularly for patients who find IVF too expensive or impersonal. The business model is built around scaling its IVC technique through strategic center openings and clinic acquisitions to capture a growing segment of the fertility market. INVO Fertility is one of the most popular companies on Eulerpool.